A recent study explores the resistance mechanisms of trastuzumab deruxtecan in HER2-amplified versus HER2-low breast cancer. Understanding these differences could inform treatment strategies and improve patient outcomes.
different diseases different escapes trastuzumab deruxtecan resistance in her2 amplified versus her2 low breast cancer
Original title: “Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer.”